Merus (NASDAQ: MRUS) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Merus to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

30.1% of Merus shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Merus has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500. Comparatively, Merus’ rivals have a beta of 8.41, indicating that their average stock price is 741% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Merus and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merus 0 1 3 0 2.75
Merus Competitors 864 3219 11678 232 2.71

Merus presently has a consensus target price of $30.25, suggesting a potential upside of 108.62%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.30%. Given Merus’ stronger consensus rating and higher possible upside, equities analysts clearly believe Merus is more favorable than its rivals.


This table compares Merus and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Merus -809.20% -119.36% -41.15%
Merus Competitors -5,273.92% -220.44% -39.38%

Earnings and Valuation

This table compares Merus and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Merus $3.01 million -$52.26 million -2.65
Merus Competitors $284.49 million $33.78 million 76.56

Merus’ rivals have higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Merus rivals beat Merus on 7 of the 12 factors compared.

About Merus

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.